openPR Logo
Press release

Alzheimer's Disease Market Set for Explosive 23.7% CAGR Growth: Key Market Drivers and Opportunities for Healthcare Companies | DelveInsight

10-07-2025 12:12 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Alzheimer's Disease Market Insights

Alzheimer's Disease Market Insights

DelveInsight's report projects the Alzheimer's disease market in the 7MM to grow at a CAGR of 23.7% from ~$5B, driven by rising prevalence and new disease-modifying therapies. Key players include Eisai, Biogen, Eli Lilly, AB Science, BioVie, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, Alzheon, UCB Pharma, Anavex Life Sciences, AgeneBio, Bristol Myers Squibb, Alzinova AB, GemVax & KAEL, among others.
Key Findings

*
Alzheimer's Disease Market size projection: As per DelveInsight's analysis, the total market size of Alzheimer's disease in the 7MM is expected to grow with a CAGR of 23.7% from ~USD 5 billion.

*
Alzheimer's Disease Market Drivers: Key market drivers of Alzheimer's disease include rising prevalence of the condition, improved diagnostic tools and biomarker research, growing awareness among healthcare professionals and patients, expanding therapeutic options with disease-modifying treatments, and favorable reimbursement policies.

*
Alzheimer's Disease Epidemiology: The report provides the total Alzheimer's disease potential pool of approximately 16 million diagnosed prevalent cases in the 7MM in 2023, with the United States representing 44% of diagnosed cases.

*
Key companies: Leading Alzheimer's disease companies, such as Eisai, Biogen, Eli Lilly, AB Science, BioVie, Cassava Sciences, TauRx Therapeutics, Novo Nordisk, Alzheon, UCB Pharma, Anavex Life Sciences, AgeneBio, and others.

*
Pipeline assets: Some of the key Alzheimer's disease therapies in the pipeline include Masitinib (AB Science), Bezisterim/NE3107 (BioVie), Simufilam/PTI-125 (Cassava Sciences), Hydromethylthionine mesylate/TRx0237 (TauRx Therapeutics), semaglutide/NN6535 (Novo Nordisk), Remternetug/LY3372993 (Eli Lilly), ALZ-801/valiltramiprosate (Alzheon), E2814 (Eisai), Bepranemab (UCB Pharma), and GV1001 (GemVax & KAEL).

*
Recent developments:

*
In October 2025, Bristol Myers Squibb received FDA Fast Track designation for BMS-986446 for Alzheimer's disease treatment.

*
In September 2025, Alzinova AB received FDA approval for its Investigational New Drug application for ALZ-101, a vaccine candidate targeting Alzheimer's disease.

*
Additionally, in August 2025, the FDA approved LEQEMBI IQLIK, a once-weekly subcutaneous autoinjector for maintenance dosing.

Stay ahead of market developments with real-time updates on regulatory approvals, clinical trial results, and competitive intelligence in the Alzheimer's therapeutic space. [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Alzheimer's Disease Market Analysis

The Alzheimer's disease market represents one of the most dynamic and rapidly evolving therapeutic areas in modern medicine. The current market, valued at ~USD 5 billion in 2025, includes approved therapies such as LEQEMBI (lecanemab) and KISUNLA (donanemab), along with traditional symptomatic treatments including galantamine, memantine, donepezil, and rivastigmine. The market demonstrates exceptional growth potential, with projections indicating a seven-fold increase by 2034, driven primarily by the introduction of disease-modifying therapies that target underlying pathological mechanisms rather than merely managing symptoms.

DelveInsight's comprehensive Alzheimer's Disease market Insights Report [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr] reveals that the United States captures the largest market share, accounting for approximately 54% of the total 7MM market in 2023, followed by EU4 countries and Japan. Among European markets, Germany leads with USD 267 million in 2023, while the UK represents the smallest market at USD 104 million. Japan's market size reached approximately USD 845 million in 2023. This geographic distribution reflects varying healthcare infrastructure, regulatory environments, and reimbursement policies across regions.

This market growth trajectory is supported by robust epidemiological data, with DelveInsight's analysis indicating 16 million diagnosed prevalent cases across the 7MM in 2023. The disease burden is expected to rise significantly, with the United States reporting 7 million cases, representing 44% of total diagnosed cases across major markets. Age-specific analysis reveals that the 75-84 age group holds the highest prevalence with nearly 3 million cases in the US alone. Gender distribution shows a pronounced female predominance, with 5 million affected females compared to 2.5 million males in the US in 2023.

Geographic segmentation across the 7MM demonstrates distinct regional characteristics. Germany accounts for 30% of diagnosed cases among the EU4 and UK markets, followed by France at 24%. The epidemiological forecast suggests continued growth in diagnosed prevalent cases, driven by improved diagnostic capabilities, increased awareness, and demographic shifts toward an aging population. Severity-specific segmentation indicates that mild cognitive impairment represents the largest patient population within EU4 and the UK, with approximately 2,560 thousand cases in 2023.

Download the Comprehensive Alzheimer's Disease Market Report 2025-2034 [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr] - Access detailed market forecasts, competitive analysis, and strategic insights to guide your investment and development decisions in this rapidly evolving therapeutic area.

Alzheimer's Disease Competitive Landscape

The competitive landscape encompasses a diverse array of therapeutic approaches, from traditional symptomatic treatments to revolutionary disease-modifying therapies. Key players include established pharmaceutical giants such as Eisai/Biogen with LEQEMBI (lecanemab) and Eli Lilly with KISUNLA (donanemab), representing the first generation of approved anti-amyloid monoclonal antibodies. These treatments have demonstrated the ability to slow cognitive decline in early-stage Alzheimer's disease, marking a paradigm shift from purely symptomatic management.

The clinical landscape features over 25 molecules in late-stage clinical trials, targeting various aspects of Alzheimer's pathology. Current treatment options span multiple mechanisms of action, including cholinesterase inhibitors (donepezil, rivastigmine, galantamine), NMDA receptor antagonists (memantine), and anti-amyloid monoclonal antibodies. The drug development pipeline showcases innovative approaches targeting tau pathology, neuroinflammation, synaptic dysfunction, and metabolic enhancement.

Development milestones in 2025 have been particularly significant, with multiple FDA approvals and designations. The FDA approved LEQEMBI IQLIK for once-weekly subcutaneous maintenance dosing, representing the first subcutaneous anti-amyloid therapy. Bristol Myers Squibb received Fast Track designation for BMS-986446, while several companies advanced their pipeline candidates through regulatory pathways. Clinical trial results continue to demonstrate the potential of combination therapies, with UCSF researchers identifying cancer drugs letrozole and irinotecan as promising candidates for Alzheimer's treatment.

Commercial arrangements include strategic partnerships, licensing deals, and collaborative research initiatives. The competitive dynamics reflect the high-risk, high-reward nature of Alzheimer's drug development, with companies pursuing diverse scientific approaches to address the complex pathophysiology of the disease. Market access considerations increasingly influence competitive positioning, with companies developing comprehensive strategies for reimbursement and patient access programs.

Request a Custom Analysis for Your Alzheimer's Disease Portfolio [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr] - Leverage our expertise to evaluate your pipeline assets, assess market positioning, and develop go-to-market strategies tailored to your specific therapeutic approach.

Alzheimer's Disease Market Drivers and Barriers

The market experiences significant momentum from multiple driving forces, most notably the rising global prevalence of Alzheimer's disease coinciding with demographic shifts toward aging populations worldwide. The expanding therapeutic landscape, particularly the emergence of disease-modifying treatments, represents a fundamental shift from symptomatic management to potentially altering disease progression. Improved diagnostic capabilities, including advanced biomarker research and neuroimaging technologies, enable earlier detection and intervention, expanding the treatable patient population.

Growing awareness among healthcare professionals, patients, and caregivers has increased diagnosis rates and treatment-seeking behaviors. Favorable reimbursement policies in key markets, particularly following regulatory approvals, support market access for innovative therapies. Investment in research and development continues to accelerate, with government initiatives and private funding driving innovation in neurodegenerative disease research.

However, significant barriers persist within the market ecosystem. Underdiagnosis and misdiagnosis remain critical challenges, with many patients remaining unidentified or receiving delayed diagnoses. The high cost of innovative treatments, ranging from $26,500 annually for lecanemab to $32,000 for donanemab, creates access barriers for many patients. Regulatory challenges continue to impact market dynamics, with varying approval processes and safety considerations across global markets.

The historical limited treatment innovation has created substantial unmet medical needs, though recent breakthroughs are beginning to address this gap. The lack of specialized care infrastructure in many regions limits patient access to appropriate diagnosis and treatment. Safety concerns, particularly amyloid-related imaging abnormalities (ARIA) associated with anti-amyloid therapies, require careful patient monitoring and may limit treatment eligibility for certain patient populations.

Alzheimer's Disease: A Critical Healthcare Challenge Demanding Innovative Solutions

Alzheimer's disease represents one of the most pressing healthcare challenges of our time, affecting over 7 million Americans and imposing a devastating burden on patients, families, and healthcare systems globally. The progressive, irreversible nature of this neurodegenerative disorder primarily impacts memory, reasoning, and cognitive abilities, making it the leading cause of dementia and responsible for 60-80% of all dementia cases. Recent breakthrough research has revealed new insights into disease mechanisms, including the identification of dendritic nanotubular networks that may contribute to amyloid-beta spread in the brain, and the connection between obesity and Alzheimer's through adipose-derived extracellular vesicles.

The therapeutic landscape is undergoing revolutionary transformation with the approval of disease-modifying treatments that target underlying pathological mechanisms. Traditional treatments, including cholinesterase inhibitors and memantine, provided only symptomatic relief without addressing disease progression. However, the recent approval of anti-amyloid therapies LEQEMBI and KISUNLA represents a paradigm shift toward treatments that can potentially slow cognitive decline and alter disease trajectory. These advances, combined with emerging pipeline candidates targeting diverse mechanisms including tau pathology, neuroinflammation, and metabolic dysfunction, offer unprecedented hope for patients and families affected by this devastating condition.

Connect with our specialized analysts [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr] to discuss market opportunities, competitive positioning, and business development strategies in the Alzheimer's disease landscape.

Scope of the Alzheimer's Disease Market Report

The comprehensive Alzheimer's Disease market report encompasses the following key areas:

*
Therapeutic Approaches - Analysis of current and emerging treatment modalities, including disease-modifying therapies, symptomatic treatments, and combination approaches

*
Patient Population Analysis - Detailed epidemiological assessment covering total diagnosed prevalent cases, age-specific, gender-specific, and severity-specific segmentation across the 7MM

*
Pipeline Analysis - Comprehensive evaluation of 138 drugs in clinical development across 182 trials, including Phase I, II, and III studies targeting various disease mechanisms

*
Market Size and Forecasting - Historical and projected market size from 2020-2034, including therapy-specific market share analysis and regional breakdowns

*
Competitive Landscape Assessment - Detailed profiles of key market players, drug development strategies, regulatory milestones, and commercial positioning

*
Market Dynamics - In-depth analysis of market drivers, barriers, opportunities, and threats affecting market growth and development

*
Regulatory Environment - Assessment of approval pathways, regulatory guidelines, and reimbursement landscapes across major markets

*
SWOT and Conjoint Analysis - Qualitative assessment of treatment options based on safety, efficacy, administration routes, and market positioning

*
Key Opinion Leader Insights - Primary research incorporating perspectives from 15+ KOLs across the 7MM to validate market trends and treatment preferences

*
Reimbursement and Market Access - Analysis of payer landscapes, coverage policies, and access programs affecting treatment adoption

*
Unmet Medical Needs - Identification of current gaps in treatment options and opportunities for therapeutic innovation

Table of Contents

1. Key Insights

2. Report Introduction

3. Alzheimer's Disease Market Overview at a Glance

4. Epidemiology and Market Forecast Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

8. Alzheimer's Disease Epidemiology and Patient Population

9. Alzheimer's Disease Patient Journey

10. Alzheimer's Disease Marketed Therapies

11. Alzheimer's Disease Emerging Therapies

12. Alzheimer's Disease: Market Analysis

13. Key Opinion Leaders' Views

14. SWOT Analysis

15. Alzheimer's Disease Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alzheimers-disease-market-set-for-explosive-237-cagr-growth-key-market-drivers-and-opportunities-for-healthcare-companies-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alzheimer's Disease Market Set for Explosive 23.7% CAGR Growth: Key Market Drivers and Opportunities for Healthcare Companies | DelveInsight here

News-ID: 4210563 • Views:

More Releases from ABNewswire

Autism Spectrum Disorder Market Poised for Strong Growth Driven by Expanding Therapeutic Pipelines and Strategic Collaborations: Market Opportunities and Unmet Needs | Delveinsight
Autism Spectrum Disorder Market Poised for Strong Growth Driven by Expanding The …
DelveInsight's Autism Spectrum Disorder market report projects strong growth across the 7MM by 2034, driven by rising prevalence, advanced screening, and late-stage pipelines. Key players include Otsuka, Johnson & Johnson, Flynn Pharma, MapLight, Roche, Axial Therapeutics, Yamo, AcadIA, DeFloria, Beyond Air, and GRIN Therapeutics, with emerging therapies like ML-004, RG7816, AB-2004, L1-79, and AJA001. Autism Spectrum Disorder Market: Key Highlights * Autism Spectrum Disorder Market size projection: As per DelveInsight's analysis, the total
Myasthenia Gravis Market Expected to Witness Substantial Growth by 2034: Know Market Drivers and Opportunities for Healthcare Executives | DelveInsight
Myasthenia Gravis Market Expected to Witness Substantial Growth by 2034: Know Ma …
The Myasthenia Gravis treatment market is projected to experience significant expansion in the coming years, propelled by the development of innovative therapies from key myasthenia gravis companies including Horizon Therapeutics, Amgen, Janssen Research & Development, Hoffmann-La Roche, Immunovant Sciences GmbH, Alexion, AstraZeneca Rare Disease, Regeneron Pharmaceuticals, Kyverna Therapeutics, and Cartesian Therapeutics, among others. DelveInsight's "Myasthenia Gravis - Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/myasthenia-gravis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides comprehensive insights into
Chronic Spontaneous Urticaria Treatment Landscape: FDA Approves RHAPSIDO, First Oral BTK Inhibitor | DelveInsight's Perspective on Market Impact, Competitive Landscape and Pipeline Therapies
Chronic Spontaneous Urticaria Treatment Landscape: FDA Approves RHAPSIDO, First …
DelveInsight's latest report highlights the transformative impact of the FDA's approval of RHAPSIDO (remibrutinib) by Novartis AG on September 30, 2025. This landmark approval marks the first oral Bruton tyrosine kinase (BTK) inhibitor specifically designed for chronic spontaneous urticaria, offering revolutionary hope for over 1.7 million patients in the United States suffering from this debilitating condition characterized by recurring hives and angioedema without identifiable triggers. Key Chronic Spontaneous Urticaria Market Highlights * RHAPSIDO's
FDA Approves Lurbinectedin + Atezolizumab: The first combination therapy for Extensive-Stage SCLC | Market Projections and Opportunities for Healthcare Executives | DelveInsight
FDA Approves Lurbinectedin + Atezolizumab: The first combination therapy for Ext …
The U.S. Food and Drug Administration's historic approval of lurbinectedin (Zepzelca) in combination with atezolizumab (Tecentriq) for maintenance treatment of extensive-stage small cell lung cancer (ES-SCLC) on October 2, 2025, represents a paradigm-shifting moment that will fundamentally transform the small cell lung cancer treatment market, according to DelveInsight Business Research LLP, a leading pharmaceutical market intelligence firm. This landmark FDA approval establishes the first combination therapy specifically designed for first-line maintenance

All 5 Releases


More Releases for Alzheimer

Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion. Data Bridge
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports. Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as